584 Participants Needed

Behavioral Interventions for Diabetes

(STIC2IT-2 Trial)

MM
NK
Overseen ByNiteesh K Choudhry, MD, PhD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Brigham and Women's Hospital
Must be taking: Oral glucose-lowering
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The overarching goal of the proposed research is to prepare the clinical pharmacist intervention for sustainable implementation and dissemination. Because the effectiveness of the intervention has already been demonstrated in a NIH Stage Model IV trial, the investigators propose an Effectiveness-Implementation Type 3 Hybrid design, in which the primary focus is on testing different implementation methods, while secondarily observing clinical effects. The investigators' overarching hypothesis is to identify the most impactful elements of a behavioral theory-informed recruitment approach, which can be replicable across clinical settings. Accordingly, the investigators propose to perform testing of a behaviorally-informed recruitment approaches in a community-based setting. Like the previous Tele-Pharmacy Intervention to Improve Treatment Adherence (STIC2IT) trial (NCT02512276), participants will be English or Spanish speaking adults ≥18 years of age identified through the electronic health record (EHR) as having poor disease control and/or poor medication adherence for diabetes. The primary care physicians of eligible patients identified through the EHR will be contacted to opt-out any patients they wish not to be included. Patients will then be randomized to each of the following conditions, such that there will be 8 total arms: (1) inclusion of a mailer primer (yes/no), (2) the most successful recruitment letter from the preliminary study using prospect theory (versus the control letter), and (3) intensity of the intervention outreach (4 calls vs. 2 calls). The investigators plan to enroll 584 participants who meet the inclusion criteria, with 73 patients per each of the 8 study arms. Patients across all arms who agree to be scheduled will receive an appointment with one of the clinical pharmacists within the established BMC pharmacist program. The primary outcome will be completion of a clinical pharmacist appointment within 8 weeks after randomization. Key secondary outcomes will include scheduled visit rates, no-show rates for scheduled appointments, medication adherence over the 3-month follow-up, and clinical outcomes, including HbA1c levels measured using EHR data in the 3 months after randomization. The medication adherence and clinical outcomes will be used for the Aim 2 evaluation.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It focuses on improving medication adherence, so it's likely you will continue your current diabetes medications.

What data supports the effectiveness of the treatment Behavioral Medication Adherence Interventions for diabetes?

Research shows that improving medication adherence through behavioral interventions can lead to better health outcomes for people with diabetes. These interventions often include strategies like positive reinforcement and simplifying treatment plans, which help patients stick to their medication schedules and improve their quality of life.12345

Is it safe to participate in behavioral interventions for diabetes?

Behavioral interventions for diabetes, which focus on improving lifestyle habits and medication adherence, are generally considered safe for humans. These interventions have been used to support better health outcomes in people with diabetes, and no significant safety concerns have been reported in the research.678910

How is the Behavioral Medication Adherence Interventions treatment for diabetes unique?

This treatment is unique because it focuses on changing patient behavior to improve medication adherence, rather than just increasing knowledge about diabetes. It emphasizes communication between patients and healthcare providers and considers individual and community factors to optimize behavior change.4671112

Research Team

NK

Niteesh K Choudhry, MD, PhD

Principal Investigator

Brigham and Women's Hospital

Eligibility Criteria

This trial is for English or Spanish speaking adults over 18 who have diabetes, are treated by a BMC primary care provider, and struggle with taking their medication as prescribed. They should also show signs of poor diabetes control. Patients will be excluded if their doctor thinks they shouldn't participate.

Inclusion Criteria

I am 18 years old or older.
I speak English or Spanish.
I am currently under the care of a BMC primary care provider.
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Randomization and Intervention

Participants are randomized into 8 arms to test different recruitment methods and intervention outreach intensities

8 weeks
1 appointment with a clinical pharmacist

Follow-up

Participants are monitored for medication adherence and clinical outcomes, including HbA1c levels

3 months

Treatment Details

Interventions

  • Behavioral Medication Adherence Interventions
Trial OverviewThe study tests different ways to get patients involved in a program that helps them stick to their diabetes medication. It compares the effects of receiving different types of recruitment letters and varying numbers of phone calls (either two or four) on making an appointment with a clinical pharmacist.
Participant Groups
8Treatment groups
Active Control
Group I: Arm 1Active Control3 Interventions
Post card; control letter; 2 calls
Group II: Arm 2Active Control3 Interventions
Post card; control letter; 4 calls
Group III: Arm 8Active Control2 Interventions
No post card; behavioral letter; 4 calls
Group IV: Arm 3Active Control3 Interventions
Post card; behavioral letter; 2 calls
Group V: Arm 4Active Control3 Interventions
Post card; behavioral letter; 4 calls
Group VI: Arm 5Active Control2 Interventions
No post card; control letter; 2 calls
Group VII: Arm 6Active Control2 Interventions
No post card; control letter; 4 calls
Group VIII: Arm 7Active Control2 Interventions
No post card; behavioral letter; 2 calls

Find a Clinic Near You

Who Is Running the Clinical Trial?

Brigham and Women's Hospital

Lead Sponsor

Trials
1,694
Recruited
14,790,000+

National Institute on Aging (NIA)

Collaborator

Trials
1,841
Recruited
28,150,000+

Boston Medical Center

Collaborator

Trials
410
Recruited
890,000+

Columbia University

Collaborator

Trials
1,529
Recruited
2,832,000+

Findings from Research

Out of 27 studies on medication adherence in Type 2 diabetes, only 13 demonstrated a significant improvement in adherence, highlighting variability in intervention effectiveness.
The study found that differences in study designs and adherence measures complicate the identification of effective interventions, suggesting a need for more tailored approaches to improve medication adherence and overall diabetes management.
Effective interventions to improve medication adherence in Type 2 diabetes: a systematic review.Williams, JL., Walker, RJ., Smalls, BL., et al.[2021]
Integrating behavioral interventions, particularly positive reinforcement, into diabetes care can significantly improve health outcomes for both youth and adults, yet these methods are often underutilized in clinical practice.
Current medical system constraints hinder the consistent application of effective behavioral principles in diabetes management, highlighting the need for increased awareness and implementation of these strategies in clinical settings.
Diabetes and Behavioral Learning Principles: Often Neglected yet Well-Known and Empirically Validated Means of Optimizing Diabetes Care Behavior.Stoeckel, M., Duke, D.[2018]
Improving adherence to treatment in type 2 diabetes is crucial for better health outcomes, as many patients struggle with complex regimens and lifestyle changes required for managing their condition.
Effective strategies to enhance adherence include patient education, simplifying treatment plans, monitoring progress, and providing ongoing support, rather than just adjusting medications.
Adherence to treatment: the key for avoiding long-term complications of diabetes.Lerman, I.[2022]

References

Effective interventions to improve medication adherence in Type 2 diabetes: a systematic review. [2021]
Diabetes and Behavioral Learning Principles: Often Neglected yet Well-Known and Empirically Validated Means of Optimizing Diabetes Care Behavior. [2018]
Adherence to treatment: the key for avoiding long-term complications of diabetes. [2022]
Design and rationale of a mixed methods randomized control trial: ADdressing Health literacy, bEliefs, adheRence and self-Efficacy (ADHERE) program to improve diabetes outcomes. [2022]
5.Bosnia and Herzegovinapubmed.ncbi.nlm.nih.gov
ADHERENCE AND QUALITY OF LIFE IN PATIENTS WITH TYPE II DIABETES MELLITUS IN NORTHERN GREECE. [2020]
Behavioral interventions for diabetes self-management. [2007]
Effective strategies for encouraging behavior change in people with diabetes. [2019]
Acceptance-based therapy: the potential to augment behavioral interventions in the treatment of type 2 diabetes. [2022]
Adherence therapy for adults with type 2 diabetes: a feasibility study of a randomized controlled trial. [2023]
10.United Statespubmed.ncbi.nlm.nih.gov
Behavioral assessment and intervention in pediatric diabetes. [2007]
11.United Statespubmed.ncbi.nlm.nih.gov
The role of behavior in diabetes care. [2019]
Assessment of patient knowledge of diabetic goals, self-reported medication adherence, and goal attainment. [2022]